New narcolepsy drug targets brain chemical to expand therapies

A new narcolepsy drug, currently in phase III trials, works by activating melanin-concentrating hormone receptors in the brain. Researchers think this mechanism could open doors for therapies targeting other neurological conditions like depression, anxiety, and PTSD. It's a fresh angle for how we tackle brain chemistry beyond just dopamine and serotonin.